Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oxford BioMedica (OtherOXBDF), Valneva (VALN) and Supernus Pharmaceuticals (SUPN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oxford BioMedica (OXBDF – Research Report), Valneva (VALN – Research Report) and Supernus Pharmaceuticals (SUPN – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oxford BioMedica (OXBDF)
Oxford BioMedica received a Buy rating and a p1170.00 price target from RBC Capital analyst Charles Weston today. The company’s shares closed last Wednesday at $8.40.
Weston has an average return of
According to TipRanks.com, Weston is ranked #11706 out of 12136 analysts.
Currently, the analyst consensus on Oxford BioMedica is a Moderate Buy with an average price target of $8.66.
See today’s best-performing stocks on TipRanks >>
Valneva (VALN)
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on Valneva today and set a price target of $8.30. The company’s shares closed last Thursday at $10.94.
According to TipRanks.com, Sharma is a 3-star analyst with an average return of
Currently, the analyst consensus on Valneva is a Moderate Buy with an average price target of $18.00.
Supernus Pharmaceuticals (SUPN)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Supernus Pharmaceuticals on February 24 and set a price target of $63.00. The company’s shares closed last Thursday at $55.75.
According to TipRanks.com, Kluska is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Supernus Pharmaceuticals with a $62.17 average price target, implying an 11.8% upside from current levels. In a report issued on February 24, Bank of America Securities also maintained a Buy rating on the stock with a $65.00 price target.
